The European Medicines Agency today approved the first Omicron-adapted Covid-19 vaccines from drugmakers Pfizer/BioNTech and Moderna to start a booster dose campaign this winter to ward off a possible new wave.
The vaccines "target Omicron's BA.1 subvariant...
The American Moderna is suing the also American Pfizer and the latter's German partner, BioNTech, for violating technology patent laws regarding the mRNA platform, through which the two companies' vaccine against Covid-19 was made.
The suit is...
Pfizer announced Monday that it has reached an agreement to acquire blood disorder drugmaker Global Blood Therapeutics for $5.4 billion.
Pfizer is looking to boost its production line to counter a potential slowdown in demand for its...
Pfizer is in advanced talks to buy drugmaker Global Blood Therapeutics for about $5 billion, the Wall Street Journal reported Friday, citing sources with knowledge of the matter.
Pfizer aims to seal the deal in the coming...
Pfizer shares rose 0.3% in pre-conference trading as the drug giant reported higher second-quarter earnings and revenue, mainly due to its coronavirus drugs Comirnaty and Paxlovid.
Net income rose to $9.91 billion, or $1.73 a share, from...
Pfizer Inc and BioNTech SE announced today that they have initiated mid-level trials of a modified Covid-19 vaccine that targets both the original variants and the BA.2 Omicron sub-variant.
The vaccine is in an initial proof-of-concept study...
